Benzodiazepine receipt in adults with psychogenic non-epileptic seizures in the USA.

EPIDEMIOLOGY EPILEPSY PSYCHIATRY

Journal

BMJ neurology open
ISSN: 2632-6140
Titre abrégé: BMJ Neurol Open
Pays: England
ID NLM: 101775450

Informations de publication

Date de publication:
2024
Historique:
received: 23 05 2024
accepted: 25 08 2024
medline: 24 9 2024
pubmed: 24 9 2024
entrez: 24 9 2024
Statut: epublish

Résumé

Characterising benzodiazepine (BZD) prescribing to individuals with psychogenic non-epileptic seizures (PNES) is important for optimising PNES outcomes, but existing data is lacking. Using a nationwide administrative claims database (2016-2022), incident PNES was defined as an International classification of diseases, tenth revision, clinical modification (ICD-10-CM) diagnosis in an inpatient or outpatient healthcare encounter after a 1-year period with no documented diagnosis. We described clinical characteristics of adults with incident PNES and estimated the prevalence of outpatient BZD treatment in the baseline year and 30-day follow-up period, with secondary analyses stratifying by baseline ES, anxiety and/or insomnia diagnoses, representing common indications for BZD receipt. We used logistic regression to evaluate predictors of post-PNES BZD receipt. Among 20 848 adults with incident PNES diagnosis, 33.1% and 15.1% received BZDs in the year and month prior to PNES diagnosis, respectively, and 18.1% received BZDs in the month following a PNES diagnosis; 5.4% of those without prior BZD prescriptions received BZDs after diagnosis. The median days' supply was 30 days, with clonazepam, alprazolam and lorazepam representing the most common BZDs prescribed after PNES. Most people who received BZDs in the month prior to PNES diagnosis remained on BZDs in the month after PNES diagnosis (62.9%), with similar findings in the subcohorts without ES, anxiety and/or insomnia. Baseline BZD receipt and anxiety disorders, but not baseline ES diagnoses, were strong independent predictors of post-PNES BZD receipt. While new BZD initiation is rare after PNES, most individuals with BZD scripts 1 month before PNES continue scripts after diagnosis.

Sections du résumé

Background UNASSIGNED
Characterising benzodiazepine (BZD) prescribing to individuals with psychogenic non-epileptic seizures (PNES) is important for optimising PNES outcomes, but existing data is lacking.
Methods UNASSIGNED
Using a nationwide administrative claims database (2016-2022), incident PNES was defined as an International classification of diseases, tenth revision, clinical modification (ICD-10-CM) diagnosis in an inpatient or outpatient healthcare encounter after a 1-year period with no documented diagnosis. We described clinical characteristics of adults with incident PNES and estimated the prevalence of outpatient BZD treatment in the baseline year and 30-day follow-up period, with secondary analyses stratifying by baseline ES, anxiety and/or insomnia diagnoses, representing common indications for BZD receipt. We used logistic regression to evaluate predictors of post-PNES BZD receipt.
Results UNASSIGNED
Among 20 848 adults with incident PNES diagnosis, 33.1% and 15.1% received BZDs in the year and month prior to PNES diagnosis, respectively, and 18.1% received BZDs in the month following a PNES diagnosis; 5.4% of those without prior BZD prescriptions received BZDs after diagnosis. The median days' supply was 30 days, with clonazepam, alprazolam and lorazepam representing the most common BZDs prescribed after PNES. Most people who received BZDs in the month prior to PNES diagnosis remained on BZDs in the month after PNES diagnosis (62.9%), with similar findings in the subcohorts without ES, anxiety and/or insomnia. Baseline BZD receipt and anxiety disorders, but not baseline ES diagnoses, were strong independent predictors of post-PNES BZD receipt.
Conclusions UNASSIGNED
While new BZD initiation is rare after PNES, most individuals with BZD scripts 1 month before PNES continue scripts after diagnosis.

Identifiants

pubmed: 39315391
doi: 10.1136/bmjno-2024-000767
pii: bmjno-2024-000767
pmc: PMC11418548
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e000767

Informations de copyright

Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Kevin Young Xu (KY)

Department of Psychiatry, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA.

Fábio A Nascimento (FA)

Department of Neurology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA.

Binx Yezhe Lin (BY)

Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, UCSF, San Francisco, California, USA.

Tae Woo Park (TW)

Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Donovan T Maust (DT)

Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan, USA.

Hillary Samples (H)

Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, USA.

Greta A Bushnell (GA)

Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, USA.

Classifications MeSH